A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03495817 |
Recruitment Status :
Completed
First Posted : April 12, 2018
Results First Posted : December 9, 2020
Last Update Posted : December 9, 2020
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Androgenetic Alopecia | Drug: ATI-50002 | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 31 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | An Open-Label Safety, Tolerability, and Efficacy Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution |
Actual Study Start Date : | March 22, 2018 |
Actual Primary Completion Date : | October 15, 2019 |
Actual Study Completion Date : | October 30, 2019 |

Arm | Intervention/treatment |
---|---|
Experimental: ATI-50002 Topical Solution
This is an open-label phase 2 study designed to evaluate the safety and efficacy of ATI- 50002 Topical Solution, 0.46% in male and female subjects with androgenetic alopecia. Subjects will be required to apply ATI-50002 study medication to their scalp twice a day for a total of 26 weeks. |
Drug: ATI-50002
ATI-50002 Topical Solution |
- Mean Change From Baseline in Target Area Hair Count (TAHC) [ Time Frame: Baseline to 26 Weeks ]Target Area Hair Count will measure the hairs/cm2 on a subject's head. Higher values represent better outcomes.
- Mean Change From Baseline in Target Area Hair Count (TAHC) [ Time Frame: Baseline to 52 Weeks ]Target Area Hair Count will measure the hairs/cm2 on a subject's head. Higher values represent better outcomes.
- Mean Change From Baseline in Cumulative Target Area Hair Width (TAHW) [ Time Frame: Baseline to 26 Weeks ]Target Area Hair Width (TAHW) will measure the cumulative width of hair in the subject's target area. Higher values represent better outcomes.
- Mean Change From Baseline in Cumulative Target Area Hair Width (TAHW) [ Time Frame: Baseline to 52 Weeks ]Target Area Hair Width (TAHW) will measure the cumulative width of hair in the subject's target area. Higher values represent better outcomes.
- Investigator Global Assessment: Total Subjects With Slightly Increased Hair Growth or Better Using a Seven-point Rating Scale [ Time Frame: Baseline to 26 Weeks ]Investigators will use a 7 point rating scale to assess hair growth following treatment with study medication. A score of +3 corresponds to significant hair growth and a score of -3 corresponds to lack of hair growth. Subjects with a score of +1 to +3 were considered to have slightly increased hair growth or better.
- Investigator Global Assessment: Total Subjects With Slightly Increased Hair Growth or Better Using a Seven-point Rating Scale [ Time Frame: Baseline to 52 Weeks ]Investigators will use a 7 point rating scale to assess hair growth following treatment with study medication. A score of +3 corresponds to significant hair growth and a score of -3 corresponds to lack of hair growth. Subjects with a score of +1 to +3 were considered to have slightly increased hair growth or better.
- Subject Self-Assessment: Total Subjects With Slightly Increased Hair Growth or Better Using a Seven-point Rating Scale [ Time Frame: Baseline to 26 Weeks ]Subjects will use a 7 point rating scale to assess hair growth following treatment with study medication. A score of +3 corresponds to significant hair growth and a score of -3 corresponds to lack of hair growth. Subjects with a score of +1 to +3 were considered to have slightly increased hair growth or better.
- Subject Self-Assessment: Total Subjects With Slightly Increased Hair Growth or Better Using a Seven-point Rating Scale [ Time Frame: Baseline to 52 Weeks ]Subjects will use a 7 point rating scale to assess hair growth following treatment with study medication. A score of +3 corresponds to significant hair growth and a score of -3 corresponds to lack of hair growth. Subjects with a score of +1 to +3 were considered to have slightly increased hair growth or better.
- Change From Baseline in Androgenetic Alopecia (AGA) Using the Norwood-Hamilton Scale [ Time Frame: Baseline to 26 Weeks ]
Measure Description: Subject's level of hair loss at baseline based on the Norwood Hamilton Scale for male subjects.
Type I: Minimal or no recession of the hairline Type II: Triangular areas of recession at the frontotemporal hairline Type III: Deep symmetrical recession at the temples are bare or only sparsely covered by hair Type IV: Frontotemporal recession is more severe than in Type III with sparse or no hair on the vertex Type V: The vertex hair loss region is separated from the frontotemporal region but is less distinct Type VI: Sparse hair remaining Type VII: The most severe form of hair loss. Lower scores represent better outcomes.
- Change From Baseline in Androgenetic Alopecia (AGA) Using the Norwood-Hamilton Scale [ Time Frame: Baseline to 52 Weeks ]
Measure Description: Subject's level of hair loss at baseline based on the Norwood Hamilton Scale for male subjects.
Type I: Minimal or no recession of the hairline Type II: Triangular areas of recession at the frontotemporal hairline Type III: Deep symmetrical recession at the temples are bare or only sparsely covered by hair Type IV: Frontotemporal recession is more severe than in Type III with sparse or no hair on the vertex Type V: The vertex hair loss region is separated from the frontotemporal region but is less distinct Type VI: Sparse hair remaining Type VII: The most severe form of hair loss. Lower scores represent better outcomes.
- Change From Baseline in Androgenetic Alopecia (AGA) Using the Sinclair Scale [ Time Frame: Baseline to 26 Weeks ]
Treating investigators will be required to rate the subject's level of hair loss at baseline based on the Sinclair scale for women.
Grade 1: is normal. This pattern is found in all girls prior to puberty but in only forty-five percent of women aged eighty or over.
Grade 2: shows a widening of the central part. Grade 3: shows a widening of the central part and thinning of the hair on either side of the central part.
Grade 4: reveals the emergence of a diffuse hair loss over the top of the scalp.
Grade 5: indicates advanced hair loss. Lower grades represent better outcomes.
- Change From Baseline in Androgenetic Alopecia (AGA) Using the Sinclair Scale [ Time Frame: Baseline to 52 Weeks ]
Treating investigators will be required to rate the subject's level of hair loss at baseline based on the Sinclair scale for women.
Grade 1: is normal. This pattern is found in all girls prior to puberty but in only forty-five percent of women aged eighty or over.
Grade 2: shows a widening of the central part. Grade 3: shows a widening of the central part and thinning of the hair on either side of the central part.
Grade 4: reveals the emergence of a diffuse hair loss over the top of the scalp.
Grade 5: indicates advanced hair loss. Lower grades represent better outcomes.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 50 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Male subjects and non-pregnant, non-nursing female subjects 18-50 years of age with a clinical diagnosis of androgenetic alopecia.
Subjects willing to agree to have a small circle of hair clipped to approx. 1mm in length on their balding spot.
Subjects willing to agree to have a permanent dot tattoo applied to their scalp to mark the center of the identified target area.
Subjects must agree to maintain the same hair style and hair care regimen during the study.
Exclusion Criteria:
Females who are nursing, pregnant, or planning to become pregnant for the duration of the study and up to 30 days after the last application of study medication.
Clinical diagnosis of alopecia areata or other non AGA forms of alopecia. Scalp hair loss on the treatment area, due to disease, injury or medical therapy.
Active skin disease of the scalp (such as psoriasis or seborrheic dermatitis) or a history of skin disease on the scalp that in the opinion of the investigator would interfere with the study assessments or efficacy or safety.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03495817
United States, Colorado | |
Aclaris Investigational Site | |
Denver, Colorado, United States, 80210 | |
United States, Oregon | |
Aclaris Investigational Site | |
Portland, Oregon, United States, 97210 | |
United States, Texas | |
Aclaris Investigational Site | |
Austin, Texas, United States, 78759 |
Study Chair: | Stuart Shanler, MD | Aclaris Therapeutics, Inc. |
Documents provided by Aclaris Therapeutics, Inc.:
Responsible Party: | Aclaris Therapeutics, Inc. |
ClinicalTrials.gov Identifier: | NCT03495817 |
Other Study ID Numbers: |
ATI-50002-AGA-201 |
First Posted: | April 12, 2018 Key Record Dates |
Results First Posted: | December 9, 2020 |
Last Update Posted: | December 9, 2020 |
Last Verified: | November 2020 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Alopecia Alopecia Areata Hypotrichosis |
Hair Diseases Skin Diseases Pathological Conditions, Anatomical |